- Submission of Manuscripts
- Abstracting & Indexing
- Editorial Information
- More ...
- Comments (0)
The journal collaborates with the following conferences:
2nd Cancer Markers & Liquid Biopsies Conference 6th-7th July 2016 in Boston, USA
Novel Cancer Therapeutics Summit 7th-9th November 2016 in San Francisco, USA
Cancer Metabolism and the Tumour Microenvironment Conference 9th-12th November 2016 in Paphos, Cyprus
The tumor micro-environment is increasingly recognized as a significant factor in cancer treatment response. Tumor oxygenation has long been known to influence sensitivity to drugs and radiation. Drug delivery is hindered by tumor vascular abnormalities and tumor desmoplasia. Recent work has uncovered means of circumventing or exploiting these changes that are unique to tumors for tumor-selective therapeutic strategies. Recent work also points to the potential for standard treatments to modulate host responses to tumors resulting in beneficial (immune responses) or counter-productive effects (vasculogenesis, tumor repopulation) on the tumor environment.
This journal provides a forum for presenting the latest results of pre-clinical and clinical investigations into the role of the tumor microenvironment on therapy responses.
Aims and Scope
Why subscribe and read
The journal presents cutting-edge reports covering the impact of the tumor microenvironment on treatment response and conversely, the effects of therapeutic interventions on the tumor microenvironment including tumor vascularization, angiogenesis, drug delivery and host immunologic responses.
This journal serves as a reference site that brings together reports of effects from different cancer treatment modalities (eg. chemo- and radiotherapy, immunotherapy) on the tumor microenvironment and the potential impact of these effects on treatment response. Such a platform provides a forum for cross-specialty exchange of information. High quality manuscripts with either positive or negative results that present an advance in the field are accepted. Rapid evaluation and publication are among the editorial goals.
- DE GRUYTER OPEN
- Emerging Science
- Type of Publication:
Instructions for Authors
Last updated on 20 January 2016
Manuscripts should be submitted to the journal via online submission system Editorial Manager available for this journal at http://www.editorialmanager.com/tmt. In case of problems, please contact the Journal Editor at email@example.com.
Authors are suggested to follow Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals from the International Committee of Medical Journal Editors (ICMJE).
Manuscript submitted to this journal should:
- contain original work - not published elsewhere in any medium (in the whole or in part) by the authors or anyone else and not under consideration for publication in any other medium;
- focus on the aims and scope of the journal;
- be clearly and correctly written - should contain all essential features of a scientific publication that is easy to understand for the target audience;
- written in English - attention to detail of the language will avoid severe misunderstandings which might lead to rejection of the paper;
- be delivered in electronic format.
The journal accepts the following publication formats:
- Research Articles
- Communications and Rapid Communications
- Reviews and Mini-Reviews
- Letters to the Editor and Amendments
The journal uses a closed single-blind peer review system (the names of the reviewers are hidden from the authors). Submitted manuscripts are reviewed by two or more experts. Reviewers are asked to recommend whether a manuscript should be accepted, revised or rejected. Although the journal uses the plagiarism detection system CrossCheck, reviewers should alert the editors if they suspect any issues relating to author misconduct such as plagiarism.
Reviewers are asked to provide detailed, constructive comments that will help both the editors make a decision on the publication and the author(s) to improve their manuscript. They should point out whether the work has serious flaws that preclude its publication, or whether additional experiments should be carried out or additional data should be collected to support the conclusions drawn.
It is important that authors include a cover letter with their manuscript. Please explain why you consider your manuscript as suitable for publication in the journal, why will your paper inspire the other members of your field, and how will it drive research forward.
The letter should contain all important details such as:
- your full name (submitted by)
- full title of article and short title
- full list of authors with affiliations
- e-mail of the corresponding author
- contact address, telephone/fax numbers of the corresponding author
- number of attached files, if there is more than one
- status: new, reviewed or accepted (with reference ID if reviewed or accepted)
Cover letter should explicitly state that the manuscript (or one with substantially the same content, by any of the authors) has not been previously published in any language anywhere and that it is not under simultaneous consideration or in press by another journal. If related work has been submitted, then we may require a preprint to be made available. Reviewers will be asked to comment on the overlap between the related submissions.
Manuscripts that have been previously rejected, or withdrawn after being returned for modification, may be resubmitted if the major criticisms have been addressed. The cover letter must state that the manuscript is a resubmission, and the former manuscript number should be provided.
Conflict of interest declaration
To ensure fair and objective decision-making, authors must declare any associations that pose a conflict of interest in connection with evaluated manuscripts (see Editorial Policy for details). Authors are encouraged to fill in the ICMJE Conflicts of Interest Form (available here) and send it in the electronic format to the Journal Editor.
Open Access License
Authors have to sign an Open Access License that is available on the journal webpage. We encourage the authors to send the signed license along with the manuscript. Please note, that no article will be published unless the Open Access License is signed.
We accept submission of text, tables and figures as separate files or as a composite file. For your initial submission, we recommend you upload your entire manuscript, including tables and figures, as a single PDF file. If you are invited to submit a revised manuscript, please provide us with individual files: an editable text and publication-quality figures.
- Text files can be submitted in the following formats: MS Word - standard DOCUMENT (.DOC) or RICH TEXT FORMAT (.RTF); PDF (not applicable for re-submitted or accepted manuscripts, see below)
- Tables should be submitted as MS Word or PDF (not applicable for re-submitted or accepted manuscripts, see below). Please note that a straight Excel file is not an acceptable format
- Graphics files can be submitted in any of the following graphic formats: EPS; BMP; JPG; TIFF; GIF or PDF. Please note that Powerpoint files are not accepted
Post acceptance, text files of the revised manuscript and tables are required for use in the production.
Authors should clearly indicate location of tables and figures in the text if these elements are given separately or at the end of the manuscript. If this information is not provided to the editorial office, we will assume that they should be left at the end of the text.
For further instructions, please carefully follow the guidelines described in Instructions for Authors.
Tumor Microenvironment and Therapy is covered by the following services:
- Baidu Scholar
- CNKI Scholar (China National Knowledge Infrastructure)
- EBSCO Discovery Service
- Genamics JournalSeek
- Google Scholar
- Meta (formerly Sciencescape)
- Naviga (Softweco)
- Primo Central (ExLibris)
- Summon (Serials Solutions/ProQuest)
- TDOne (TDNet)
- Ulrich's Periodicals Directory/ulrichsweb
- WorldCat (OCLC)
Eric Jacques Bernhard*, MD, Bethesda, USA
Theresa Busch, Perelman School of Medicine, University of Pennsylvania, USA
Editorial Advisory Board
Martin Brown, Stanford University, CA, USA
Jan Bussink, Radboud University Nijmegen Medical Centre, The Netherlands
Cameron J. Koch, University of Pennsylvania, Philadelphia, PA, USA
Nils Cordes, National Center for Radiation Research in Oncology, Dresden, Germany
Sydney Evans, University of Pennsylvania, Philadelphia, PA, USA
Chandan Guha, Albert Einstein College of Medicine of Yeshiva University, New York, USA
James W. Hodge, National Cancer Institute, NIH, Bethesda, MD, USA
In Ah Kim, Seoul National University College of Medicine, Seoul, Republic of Korea
Bert van der Kogel, University of Wisconsin, Madison, WI, USA
Ruth Muschel, University of Oxford, UK
Jacques Pouyssegur, Institute of Research on Cancer and Aging (IRCAN), Nice, France
Celeste Simon, University of Pennsylvania, Philadelphia, PA, USA
Brad Wouters, Ontario Institute for Cancer Research, Canada
Iris Eke, Dresden Medical Faculty Carl Gustav Carus, Dresden University of Technology, Dresden, Germany
Frederik Pruijn, The University of Auckland, New Zealand
Naseer Qayum, University of Oxford, UK
Richard C. A. Sainson, MedImmune Limited, Cambridge, UK
DE GRUYTER OPEN
Bogumiła Zuga 32A Str.
01-811 Warsaw, Poland
T: +48 22 701 50 15
*Dr. Bernhard is serving in his personal capacity